Novo Nordisk's data on subcutaneous and oral amycretin shows significant weight loss potential

From GlobeNewswire: 2025-06-20 19:34:00

Novo Nordisk announced the publication of data on the safety, tolerability, and weight loss potential of subcutaneous and oral amycretin in people with overweight or obesity. The findings from the clinical trials were presented at the American Diabetes Association Scientific Sessions. The results showed that amycretin appeared tolerable with a safety profile consistent with other GLP-1 and amylin receptor agonists, and participants demonstrated significant weight loss with both subcutaneous and oral administration. Novo Nordisk plans to advance amycretin into phase 3 trials to further investigate its potential as a therapeutic option for weight management.



Read more at GlobeNewswire: Novo Nordisk’s subcutaneous and oral amycretin data